Internal Medicine, Hematology & Oncology · San Diego, CA
NPI
1912181173
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
200 W Arbor Dr
San Diego, CA, 92103
Phone (858) 822-6100
Groups this clinician bills Medicare through
Medicare paid, 2024
$70K
1,219 services
Medicare patients, 2024
335
Average age 73
Drug cost, 2024
$9.6M
1,163 prescriptions
Company payments, 2025
$356
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael Y Choi was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 343 times for 150 patients. In total Michael Y Choi billed 1,219 services in 23 codes, and Medicare paid $70K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-11-12.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 343 | 150 | $12.92 | $4,433 |
| 99214 Office E&M - Established | Facility | 295 | 174 | $73.31 | $22K |
| 99215 Office E&M - Established | Facility | 104 | 55 | $111.30 | $12K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 86 | 48 | $12.83 | $1,104 |
| 99232 Hospital E&M - Subsequent | Facility | 60 | 35 | $61.60 | $3,696 |
| 99213 Office E&M - Established | Facility | 50 | 44 | $47.09 | $2,355 |
| 99222 Hospital E&M - Initial | Facility | 46 | 46 | $103.03 | $4,740 |
| 99215 Office E&M - Established | Office | 39 | 26 | $152.68 | $5,955 |
| 99214 Office E&M - Established | Office | 28 | 26 | $100.42 | $2,812 |
| 99233 Hospital E&M - Subsequent | Facility | 27 | 15 | $90.09 | $2,433 |
| 99213 Office E&M - Established | Office | 26 | 21 | $74.67 | $1,941 |
| 99204 Office E&M - New | Facility | 20 | 20 | $105.81 | $2,116 |
| 99231 Hospital E&M - Subsequent | Facility | 16 | 12 | $37.44 | $599 |
| 99212 Office E&M - Established | Office | 16 | 11 | $39.15 | $626 |
By year: 2022 $55K for 684 services; 2023 $61K for 742 services; 2024 $70K for 1,219 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael Y Choi prescribed most often to Medicare patients was Calquence (Acalabrutinib Maleate), with 175 prescriptions and refills. In total Michael Y Choi wrote 1,163 Medicare prescriptions that cost $9.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Calquence Acalabrutinib Maleate | 175 | 175 | 18 | $2.4M |
| Brukinsa Zanubrutinib | 171 | 172 | 19 | $1.9M |
| Imbruvica Ibrutinib | 147 | 157 | 16 | $2.2M |
| Venclexta Venetoclax | 116 | 116 | 17 | $1.6M |
| Acyclovir Generic | 66 | 176 | 20 | $2,875 |
| Hydroxyurea Generic | 54 | 107 | 13 | $2,208 |
| Eliquis Apixaban | 50 | 76 | Under 11 | $43K |
| Valacyclovir Valacyclovir Hcl | 42 | 93 | 13 | $4,702 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 27 | 39 | Under 11 | $65.11 |
| Jaypirca Pirtobrutinib | 19 | 19 | Under 11 | $383K |
| Fluticasone Propionate Generic | 14 | 31 | Under 11 | $135 |
| Allopurinol Generic | 13 | 19 | Under 11 | $67.3 |
| Jakafi Ruxolitinib Phosphate | 12 | 12 | Under 11 | $211K |
| Hydrochlorothiazide Generic | 12 | 28 | Under 11 | $9.34 |
| Azithromycin Generic | 11 | 11 | Under 11 | $31.32 |
Brand drugs: 762 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael Y Choi $356 ($356 in general payments such as food, travel and fees) from 10 companies. The largest payer was Rigel Pharmaceuticals, Inc. with $176.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.